Expression of CXCR4, MMP-13 and β-catenin in different histological subtypes of facial basal cell carcinoma

Romanian Journal of Morphology and Embryology

Volumn 54, Issue 4, 2013, Pages 939-951

  Ciurea, M E ^a   Cernea, Daniela ^b   Georgescu, C C ^a   Cotoi, O S ^c   Patrascu V ^d   Parvanescu H ^a   Popa, D ^a   Parvanescu V ^a   Ciurea, Raluca Niculina ^d   Mercut R ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^b EMERGENCY COUNTY HOSPITAL   (Romania)

^c UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d Department of Dermatology ^*  (Romania)

Author keywords

catenin; Basal cell carcinoma; CXCR4; Histological subtypes; Immunohistochemistry; MMP 13

Indexed keywords

BETA CATENIN; CHEMOKINE RECEPTOR CXCR4; COLLAGENASE 3; CXCR4 PROTEIN, HUMAN; MMP13 PROTEIN, HUMAN;

AGED; ARTICLE; BASAL CELL CARCINOMA; ENZYMOLOGY; FACE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BETA CATENIN; CARCINOMA, BASAL CELL; FACE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 13; MIDDLE AGED; RECEPTORS, CXCR4; SKIN NEOPLASMS;

EID: 84891595048     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Katalinic A, Kunze U, Schäfer T, Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig- Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer), Br J Dermatol, 2003, 149(6):1200-1206.
2. Raasch BA, Buettner PG, Garbe C, Basal cell carcinoma: histological classification and body-site distribution, Br J Dermatol, 2006, 155(2):401-407.
3. Lear JT, Harvey I, de Berker D, Strange RC, Fryer AA, Basal cell carcinoma, J R Soc Med, 1998, 91(11):585-588.
4. Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ, Aggressive basal cell carcinoma: presentation, pathogenesis, and management, Cancer Metastasis Rev, 2004, 23(3-4):389-402.
5. Malone JP, Fedok FG, Belchis DA, Maloney ME, Basal cell carcinoma metastatic to the parotid: report of a new case and review of the literature, Ear Nose Throat J, 2000, 79(7): 511-515, 518-519.
6. Rippey JJ, Why classify basal cell carcinomas? Histopathology, 1998, 32(5):393-398.
7. Woodhouse EC, Chuaqui RF, Liotta LA, General mechanisms of metastasis, Cancer, 1997, 80(8 Suppl):1529-1537.
8. Wang Z, Ma Q, Beta-catenin is a promising key factor in the SDF-1/CXCR4 axis on metastasis of pancreatic cancer, Med Hypotheses, 2007, 69(4):816-820.
9. Chu CY, Cha ST, Chang CC, Hsiao CH, Tan CT, Lu YC, Jee SH, Kuo ML, Involvement of matrix metalloproteinase- 13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells, Oncogene, 2007, 26(17): 2491-2501.
10. Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, Ratajczak J, Ratajczak MZ, Janowska-Wieczorek A, Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1- CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases, Stem Cells, 2006, 24(5):1254-1264.
11. Tang CH, Tan TW, Fu WM, Yang RS, Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis, Carcinogenesis, 2008, 29(1):35-43.
12. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR, The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes, Proc Natl Acad Sci U S A, 1997, 94(5):1925-1930.
13. Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM, Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines, J Biol Chem, 1998, 273(7):4282-4287.
14. Hesselgesser J, Halks-Miller M, DelVecchio V, Peiper SC, Hoxie J, Kolson DL, Taub D, Horuk R, CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons, Curr Biol, 1997, 7(2):112-121.
15. Horuk R, Chemokine receptors, Cytokine Growth Factor Rev, 2001, 12(4):313-335.
16. Murdoch C, CXCR4: chemokine receptor extraordinaire, Immunol Rev, 2000, 177:175-184.
17. Barbero S, Bonavia R, Bajetto A, Porcile C, Pirani P, Ravetti JL, Zona GL, Spaziante R, Florio T, Schettini G, Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt, Cancer Res, 2003, 63(8):1969-1974.
18. Chen GS, Yu HS, Lan CC, Chow KC, Lin TY, Kok LF, Lu MP, Liu CH, Wu MT, CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma, Br J Dermatol, 2006, 154(5):910-918.
19. Jiang YP, Wu XH, Shi B, Wu WX, Yin GR, Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression, Gynecol Oncol, 2006, 103(1):226-233.
20. Koishi K, Yoshikawa R, Tsujimura T, Hashimoto-Tamaoki T, Kojima S, Yanagi H, Yamamura T, Fujiwara Y, Persistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer, World J Gastroenterol, 2006, 12(47):7585-7590.
21. Ohira S, Sasaki M, Harada K, Sato Y, Zen Y, Isse K, Kozaka K, Ishikawa A, Oda K, Nimura Y, Nakanuma Y, Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromalderived factor-1 released in stroma, Am J Pathol, 2006, 168(4):1155-1168.
22. Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D, Khayat D, Le Chevalier T, Soria JC, Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome, Ann Oncol, 2004, 15(4):613-617.
23. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, Castello G, Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma, Clin Cancer Res, 2005, 11(5):1835-1841.
24. Saur D, Seidler B, Schneider G, Algül H, Beck R, Senekowitsch-Schmidtke R, Schwaiger M, Schmid RM, CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer, Gastroenterology, 2005, 129(4):1237-1250.
25. Kossard S, Epstein Jr. EH, Cerio R, Yu LL, Weedon D, Basal cell carcinoma. In: LeBoit PE, Burg G, Weedon D, Sarasin A (eds), Pathology and genetics of skin tumours, World Health Organization Classification of Tumors, IARC Press, Lyon, 2006, 13-19.
26. Saldanha G, Fletcher A, Slater DN, Basal cell carcinoma: a dermatopathological and molecular biological update, Br J Dermatol, 2003, 148(2):195-202.
27. Remmele W, Stegner HE, Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue, Pathologe, 1987, 8(3):138-140.
28. Jacobs GH, Rippey JJ, Altini M, Prediction of aggressive behavior in basal cell carcinoma, Cancer, 1982, 49(3):533-537.
29. Choi JH, Kim YJ, Kim H, Nam SH, Choi YW, Distribution of basal cell carcinoma and squamous cell carcinoma by facial esthetic unit, Arch Plast Surg, 2013, 40(4):387-391.
30. Narayanan DL, Saladi RN, Fox JL, Ultraviolet radiation and skin cancer, Int J Dermatol, 2010, 49(9):978-986.
31. Bastiaens MT, Hoefnagel JJ, Bruijn JA, Westendorp RG, Vermeer BJ, Bouwes Bavinck JN, Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors, J Invest Dermatol, 1998, 110(6):880-884.
32. McCormack CJ, Kelly JW, Dorevitch AP, Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes, Arch Dermatol, 1997, 133(5):593-596.
33. Avniel S, Arik Z, Maly A, Sagie A, Basst HB, Yahana MD, Weiss ID, Pal B, Wald O, Ad-El D, Fujii N, Arenzana- Seisdedos F, Jung S, Galun E, Gur E, Peled A, Involvement of the CXCL12/CXCR4 pathway in the recovery of skin following burns, J Invest Dermatol, 2006, 126(2):468-476.
34. Takekoshi T, Wu X, Mitsui H, Tada Y, Kao MC, Sato S, Dwinell MB, Hwang ST, CXCR4 negatively regulates keratinocyte proliferation in IL-23-mediated psoriasiform dermatitis, J Invest Dermatol, 2013, 133(11):2530-2537.
35. Mueller MM, Fusenig NE, Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells, Differentiation, 2002, 70(9-10):486-497.
36. Chu CY, Cha ST, Lin WC, Lu PH, Tan CT, Chang CC, Lin BR, Jee SH, Kuo ML, Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1/2-NF-kappaB/ interleukin-6 pathway, Carcinogenesis, 2009, 30(2):205-213.
37. Oh CK, Kwon YW, Kim YS, Jang HS, Kwon KS, Expression of basic fibroblast growth factor, vascular endothelial growth factor, and thrombospondin-1 related to microvessel density in nonaggressive and aggressive basal cell carcinomas, J Dermatol, 2003, 30(4):306-313.
38. Staibano S, Boscaino A, Salvatore G, Orabona P, Palombini L, De Rosa G, The prognostic significance of tumor angiogenesis in nonaggressive and aggressive basal cell carcinoma of the human skin, Hum Pathol, 1996, 27(7): 695-700.
39. Vaalamo M, Mattila L, Johansson N, Kariniemi AL, Karjalainen-Lindsberg ML, Kähäri VM, Saarialho-Kere U, Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds, J Invest Dermatol, 1997, 109(1):96-101.
40. Ravanti L, Häkkinen L, Larjava H, Saarialho-Kere U, Foschi M, Han J, Kähäri VM, Transforming growth factor-beta induces collagenase-3 expression by human gingival fibroblasts via p38 mitogen-activated protein kinase, J Biol Chem, 1999, 274(52):37292-37300.
41. Ravanti L, Toriseva M, Penttinen R, Crombleholme T, Foschi M, Han J, Kähäri VM, Expression of human collagenase-3 (MMP-13) by fetal skin fibroblasts is induced by transforming growth factor beta via p38 mitogen-activated protein kinase, FASEB J, 2001, 15(6):1098-1100.
42. Toriseva MJ, Ala-aho R, Karvinen J, Baker AH, Marjomäki VS, Heino J, Kähäri VM, Collagenase-3 (MMP-13) enhances remodeling of three-dimensional collagen and promotes survival of human skin fibroblasts, J Invest Dermatol, 2007, 127(1):49-59.
43. Toriseva M, Laato M, Carpén O, Ruohonen ST, Savontaus E, Inada M, Krane SM, Kähäri VM, MMP-13 regulates growth of wound granulation tissue and modulates gene expression signatures involved in inflammation, proteolysis, and cell viability, PLoS One, 2012, 7(8):e42596.
44. Egeblad M, Werb Z, New functions for the matrix metalloproteinases in cancer progression, Nat Rev Cancer, 2002, 2(3):161-174.
45. Kerkelä E, Saarialho-Kere U, Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer, Exp Dermatol, 2003, 12(2):109-125.
46. Airola K, Johansson N, Kariniemi AL, Kähäri VM, Saarialho- Kere UK, Human collagenase-3 is expressed in malignant squamous epithelium of the skin, J Invest Dermatol, 1997, 109(2):225-231.
47. Balbín M, Pendás AM, Uría JA, Jiménez MG, Freije JP, López-Otín C, Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors, APMIS, 1999, 107(1): 45-53.
48. Alvarez Suárez ML, González Vázquez LO, Barbón García JJ, Vázquez Rojo J, Lamelas Suárez-Pola ML, Vizoso Piñeiro FJ, Collagenase-3 (MMP-13) expression in epithelial cancers of the eyelids, Arch Soc Esp Oftalmol, 2004, 79(6):281-288.
49. Zlatarova ZI, Softova EB, Dokova KG, Messmer EM, Expression of matrix metalloproteinase-1, -9, -13, and tissue inhibitor of metalloproteinases-1 in basal cell carcinomas of the eyelid, Graefes Arch Clin Exp Ophthalmol, 2012, 250(3): 425-431.
50. Hattori Y, Nerusu KC, Bhagavathula N, Brennan M, Hattori N, Murphy HS, Su LD, Wang TS, Johnson TM, Varani J, Vascular expression of matrix metalloproteinase-13 (collagenase-3) in basal cell carcinoma, Exp Mol Pathol, 2003, 74(3):230-237.
51. Foda HD, Zucker S, Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis, Drug Discov Today, 2001, 6(9):478-482.
52. Hadler-Olsen E, Winberg JO, Uhlin-Hansen L, Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets, Tumour Biol, 2013, 34(4): 2041-2051.
53. Peifer M, Polakis P, Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus, Science, 2000, 287(5458):1606-1609.
54. Ozawa M, Baribault H, Kemler R, The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species, EMBO J, 1989, 8(6):1711-1717.
55. Behrens J, von Kries JP, Kühl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W, Functional interaction of betacatenin with the transcription factor LEF-1, Nature, 1996, 382(6592):638-642.
56. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A, The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway, Proc Natl Acad Sci U S A, 1999, 96(10):5522-5527.
57. van Noort M, Clevers H, TCF transcription factors, mediators of Wnt-signaling in development and cancers, Dev Biol, 2002, 244(1):1-8.
58. Tetsu O, McCormick F, Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells, Nature, 1999, 398(6726): 422-426.
59. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, Matrisian LM, The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors, Oncogene, 1999, 18(18):2883-2891.
60. Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ, Boman BM, Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer, Cancer Res, 2001, 61(24):8664-8667.
61. Takeda K, Yasumoto K, Takada R, Takada S, Watanabe K, Udono T, Saito H, Takahashi K, Shibahara S, Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a, J Biol Chem, 2000, 275(19):14013-14016.
62. Roose J, Huls G, van Beest M, Moerer P, van der Horn K, Goldschmeding R, Logtenberg T, Clevers H, Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1, Science, 1999, 285(5435):1923-1926.
63. Yasumoto K, Takeda K, Saito H, Watanabe K, Takahashi K, Shibahara S, Microphthalmia-associated transcription factor interacts with LEF-1, a mediator of Wnt signaling, EMBO J, 2002, 21(11):2703-2714.
64. Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L, Sakamoto D, Caothien RH, Fuller JH, Reinhard C, Garcia PD, Randazzo FM, Escobedo J, Fantl WJ, Williams LT, Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta-catenin signaling is activated in human colon tumors, Proc Natl Acad Sci U S A, 2001, 98(26):14973-14978.
65. Doglioni C, Piccinin S, Demontis S, Cangi MG, Pecciarini L, Chiarelli C, Armellin M, Vukosavljevic T, Boiocchi M, Maestro R, Alterations of beta-catenin pathway in non-melanoma skin tumors: loss of alpha-ABC nuclear reactivity correlates with the presence of beta-catenin gene mutation, Am J Pathol, 2003, 163(6):2277-2287.
66. Fukumaru K, Yoshii N, Kanzaki T, Kanekura T, Immunohistochemical comparison of beta-catenin expression by human normal epidermis and epidermal tumors, J Dermatol, 2007, 34(11):746-753.
67. El-Bahrawy M, El-Masry N, Alison M, Poulsom R, Fallowfield M, Expression of beta-catenin in basal cell carcinoma, Br J Dermatol, 2003, 148(5):964-970.
68. Saldanha G, Ghura V, Potter L, Fletcher A, Nuclear betacatenin in basal cell carcinoma correlates with increased proliferation, Br J Dermatol, 2004, 151(1):157-164.
69. Boonchai W, Walsh M, Cummings M, Chenevix-Trench G, Expression of beta-catenin, a key mediator of the WNT signaling pathway, in basal cell carcinoma, Arch Dermatol, 2000, 136(7):937-938.
70. Brinkhuizen T, van den Hurk K, Winnepenninckx VJ, de Hoon JP, van Marion AM, Veeck J, van Engeland M, van Steensel MA, Epigenetic changes in basal cell carcinoma affect SHH and WNT signaling components, PLoS One, 2012, 7(12):e51710.
71. Oh ST, Kim HS, Yoo NJ, Lee WS, Cho BK, Reichrath J, Increased immunoreactivity of membrane type-1 matrix metalloproteinase (MT1-MMP) and β-catenin in high-risk basal cell carcinoma, Br J Dermatol, 2011, 165(6):1197-1204.
72. Madan V, Lear JT, Szeimies RM, Non-melanoma skin cancer, Lancet, 2010, 375(9715):673-685.
73. Choi HN, Kim KR, Lee JH, Park HS, Jang KY, Chung MJ, Hwang SE, Yu HC, Moon WS, Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex, Oncol Rep, 2009, 21(1):57-63.
74. Wang L, Li CL, Wang L, Yu WB, Yin HP, Zhang GY, Zhang LF, Li S, Hu SY, Influence of CXCR4/SDF-1 axis on E-cadherin/ β-catenin complex expression in HT29 colon cancer cells, World J Gastroenterol, 2011, 17(5):625-632.